ReviewCytokine2019
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Review in Cytokine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Endothelial progenitor cells in the host defense response.Pharmacology & therapeutics · 2023Review
- Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study.Biomedicines · 2022Article
- Computational insight of dexamethasone against potential targets of SARS-CoV-2.Journal of biomolecular structure & dynamics · 2022Article
- The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis.Frontiers in immunology · 2022Article
- Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.International reviews of immunology · 2022Article
- GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism.Trends in endocrinology and metabolism: TEM · 2021Review
- Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review.Chinese medicine · 2021Review
- Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- On the role of bacterial metalloproteases in COVID-19 associated cytokine storm.Cell communication and signaling : CCS · 2021Article
- Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.International journal of medical sciences · 2021Review
- COVID-19 Therapy: Could a Copper Derivative of ChlorophyllFrontiers in medicine · 2021Article
- Dengue Virus Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent NETosis-Mediated Inflammation in Mice.Frontiers in immunology · 2021Article
- Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.Human immunology · 2020Review
- A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases.Cytokine · 2020Review
- ADAM17 cytoplasmic domain modulates Thioredoxin-1 conformation and activity.Redox biology · 2020Article
- Surgical treatment of thoracolumbar fracture with incomplete lower limb paralysis in a patient with COVID-19.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2020Article
- Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.Biochemical pharmacology · 2020Review
- Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.In vivo (Athens, Greece) · 2020Review
- Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.Frontiers in immunology · 2020Review
- COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?Ecancermedicalscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease fatality associated with Ebola, SARS-CoV and dengue infections in humans is attributed to a cytokine storm that is triggered by excessive pro-inflammatory responses. Interleukin (IL)-6 acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signaling, respectively. Hence, IL-6 is assumed to provide a target for a broad range of antiviral agents. Available immunosuppressive antivirals are directed to control an often exaggerated pro-inflammatory response that gives rise to complex clinical conditions such as lymphocytopenia. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling. In this review, we propose that the tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.